Home Cart Sign in  
Chemical Structure| 1610759-22-2 Chemical Structure| 1610759-22-2

Structure of CFI-402257
CAS No.: 1610759-22-2

Chemical Structure| 1610759-22-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CFI-402257 is a novel and selective Mps1 inhibitor with Ki value of 0.1 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CFI-402257

CAS No. :1610759-22-2
Formula : C28H30N6O3
M.W : 498.58
SMILES Code : O=C(NC1CC1)C2=CC=C(C3=C4N=C(OC5=CC=CN=C5)C=C(NC[C@H]6C[C@](C)(O)C6)N4N=C3)C=C2C
MDL No. :MFCD31382135
InChI Key :PMQUGSPFUBGJCZ-UHFFFAOYSA-N
Pubchem ID :118086034

Safety of CFI-402257

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of CFI-402257

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 cells 0-1000 nM 72 hours Inhibits PI4KIIα activity, reduces exosome secretion PMC11223027
Mouse aortic vascular smooth muscle cell line (MOVAS) Various concentrations To evaluate the effect of CFI-402257 on VSMC contractile marker expression, proliferation, and migration, results showed it could dose-dependently increase contractile marker expression and inhibit proliferation and migration PMC11809377
RB1-deficient ER+ breast cancer cell lines 150 nM 72 hours To assess the impact of RB1 loss on sensitivity to CFI-402257, results showed that RB1-deficient cells were more sensitive to CFI-402257, inducing higher levels of apoptosis PMC9451148
ER+ breast cancer cell lines 150 nM 48 hours To evaluate the sensitivity of CDK4/6i-resistant cells to CFI-402257, results showed that CFI-402257 induced premature chromosome segregation, increased DNA damage, and cell death PMC9451148
Myla3676 cells 10 μM or 20 μM 48 hours Inhibited cell proliferation, induced G2/M phase arrest, promoted apoptosis PMC11905054
Jurkat cells 10 μM or 20 μM 48 hours Investigate Nr1d1 binding to the GATA3 promoter region in human Jurkat cells PMC11905054
Hep3B, Huh7, MHCC97L, PLC/PRF/5, Hepa1-6 Various concentrations 5 days Evaluated cell proliferation inhibition effects PMC9371652
MHCC97L 500 nM 48 hours Induced micronuclei formation and DNA damage PMC9371652
MDA-MB-436 150 nM 72 hours PMC5816201
MDA-MB-468 150 nM 72 hours Evaluate cytotoxicity of 806-PE38 on MDA-MB-468 cells, IC50 was 7 ng/mL PMC5816201
HCT116 cells 100 nM 2 days To evaluate the effect of terbinafine on CRC cell viability, results showed that terbinafine significantly reduced the viability of HCT116 cells. PMC5373378
HCT116 cells 200 nM 2 hours To evaluate the effect of terbinafine on CRC cell viability, results showed that terbinafine significantly reduced the viability of HCT116 cells. PMC5373378
MDA-MB-231 150 nM 72 hours Evaluate the toxicity of HTCG@TA on MDA-MB-231 cells, results showed only 32% cell survival PMC5816201
MCF-7 cells 0-1000 nM 72 hours K-145 reduced nuclear S1P, almost completely blocked H3-K9ac, HIF1α associated spheroid formation, and enhanced dead cells PMC11223027
HMEC cells 0-1000 nM 72 hours Evaluate the cytotoxicity of CFI-402257, results showed lower toxicity in HMEC cells PMC11223027
Normal mesothelial cells 20-40 nM 5 days CFI-402257 had no significant effect on normal mesothelial cells at the same concentrations. PMC5690838
Malignant mesothelioma cell lines 100 nM 30 minutes to 72 hours CFI-402257-mediated inhibition of Mps-1 resulted in abrogation of the mitotic checkpoint, premature progression through mitosis, marked aneuploidy and mitotic catastrophe. PMC5690838
U87 cells 1 μM 48 hours To assess the accumulation of penciclovir in transduced cells, results showed no accumulation of penciclovir in transduced cells PMC9290216
U251 cells 0.5 μM 48 hours Evaluate the inhibitory effect of CPI-455 on U251 cell proliferation, showing TMZ-resistant U251 cells are more sensitive to CPI-455 PMC9290216

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Carotid artery wire injury model and HFD-fed ApoE−/− mice 1, 2, or 4 mg/kg body weight Oral Once daily for 28 days (wire injury model) or 12 weeks (atherosclerosis model) To evaluate the effect of CFI-402257 on postinjury neointimal formation and atherosclerosis, results showed it significantly inhibited neointimal formation and atherosclerotic plaque area without impairing reendothelialization PMC11809377
SCID mice MCF7 RB1-deficient xenograft model 6 mg/kg (daily) and 25 mg/kg (2 days on/5 days off) Oral administration Daily or 2 days on/5 days off, for up to 38 days To evaluate the antitumor activity of CFI-402257 in RB1-deficient tumors, results showed that CFI-402257 significantly inhibited tumor growth PMC9451148
SCID beige mice TCL xenograft model 6 mg/kg/day Oral Once daily for one week Inhibited tumor growth, reduced tumor volume and weight PMC11905054
BALB/cAnN-nu mice HCC model 6 mg/kg/day Oral Once daily for 19 days Assessed the inhibitory effect of CFI-402257 on HCC growth PMC9371652
Mice MDA-MB-231 human TNBC xenograft model 6 mg/kg oral Once daily for 22 days CFI-402257 significantly inhibited tumor growth with a TGI of 89% PMC5373378
BALB/c nude mice MDA-MB-231 xenograft model 1 mg/kg Oral and intraperitoneal injection Once daily for 28 days Evaluate the antitumor effect of CFI-402257 and AICAR combination therapy, results showed significant tumor growth inhibition PMC11223027
BALB/c mice Orthotopic, syngeneic model of malignant mesothelioma 7 mg/kg Oral gavage Daily, till study end-point CFI-402257 significantly reduced tumor growth as a single agent and showed enhanced effect when combined with cisplatin+pemetrexed. PMC5690838
Mice HCT116 and HT29 xenograft models 5.5 mg/kg and 6.5 mg/kg oral Once daily for 21 days CFI-402257 showed dose-dependent tumor growth inhibition in the HCT116 model and a wide range of tumor growth inhibition in the HT29 model PMC4948001

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.01mL

0.40mL

0.20mL

10.03mL

2.01mL

1.00mL

20.06mL

4.01mL

2.01mL

References

 

Historical Records

Categories